



Market Announcement

20 July 2020

Sienna Cancer Diagnostics Limited (ASX: SDX) – Suspension from Official Quotation

Description

The securities of Sienna Cancer Diagnostics Limited ('SDX') will be suspended from quotation at the close of trading today, Monday, 20 July 2020, in accordance with Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which BARD1 Life Sciences Limited will acquire all of the issued shares in SDX.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



Sienna Cancer Diagnostics Limited
ABN 74 099 803 460

23 Normanby Rd
Notting Hill VIC 3168

Telephone +61 3 9548 7586

20 July 2020

The Manager
Australian Securities Exchange
Company Announcement Office
Rialto Towers
Level 4
525 Collins Street
MELBOURNE VIC 3000

Dear Sir / Madam

Sienna Cancer Diagnostics Limited – Request for suspension from trade

Sienna Cancer Diagnostics Limited (**Sienna**) wishes to notify the Australian Securities Exchange Limited (**ASX**) that on 20 July 2020 the Federal Court of Australia (**Court**) approved the scheme of arrangement proposed pursuant to Section 411 of the *Corporations Act 2001* between Sienna and its ordinary shareholders on the terms of the Merger Implementation Agreement dated 8 April 2020 between Sienna and BARD1 Life Sciences Limited (**BARD1**) (**Scheme**). Under the Scheme, BARD1 will acquire all the shares in Sienna.

The Scheme was previously agreed to by the passing of a resolution at a meeting of Sienna shareholders held on 15 July 2020. The resolution was passed by a majority in number of shareholders present and voting (either in person or by proxy) and by 75% of the votes cast on the resolution.

The Scheme became effective earlier today when a copy of the court order was lodged with the Australian Securities and Investments Commission (**ASIC**).

Pursuant to ASX Listing Rule 17.2, Sienna therefore requests that all Sienna shares quoted on ASX be suspended from trading on ASX as of the close of trade today.

It is expected that the suspension will last until the matters involving implementation of the Scheme are completed at the end of 28 July 2020 at which time a request will be issued to remove Sienna from the official list of ASX.

Sienna is not aware of any reason why Sienna shares should not be suspended in accordance with this request.

Yours faithfully,

Tony Di Pietro
Executive Director, Chief Financial Officer and Company Secretary
Sienna Cancer Diagnostics Limited